tipifarnib: Clinical Trials

4 trials of tipifarnib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Completed 4
Phase 21Completed 1

Follow tipifarnib: new trials by email Literature Review of tipifarnib trials Research Report on tipifarnib

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
alemtuzumab, arsenic trioxide, azacitidine - Leukemia, Myelodysplastic Syndromes
Phase 2 / Phase 3CompletedThe University of New South Wales20002006-08-012013-08-26
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
Clinical Observation, Tipifarnib - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia
Phase 3CompletedNational Cancer Institute (NCI)1442004-08-182026-07-14
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Tipifarnib;Zarnestra; R115777 - Acute Myeloid Leukemia
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.4572004-01-012016-09-14
Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer
Gemcitabine with R115777, Gemcitabine with Placebo - Pancreatic Neoplasms
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.6881999-11-012011-05-19

Conditions studied

Leukemia, Myeloid, Acute (3)  ·  Anemia, Refractory, with Excess of Blasts (2)  ·  Leukemia, Erythroblastic, Acute (2)  ·  Leukemia, Megakaryoblastic, Acute (2)  ·  Leukemia, Monocytic, Acute (2)  ·  Leukemia, Myelomonocytic, Acute (2)  ·  Congenital Abnormalities (1)  ·  Leukemia (1)  ·  Leukemia, Basophilic, Acute (1)  ·  Leukemia, Eosinophilic, Acute (1)  ·  Myelodysplastic Syndromes (1)  ·  Pancreatic Neoplasms (1)

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2)  ·  National Cancer Institute (NCI) (1)  ·  The University of New South Wales (1)

Countries

Israel (1)  ·  Peru (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Alan K. Burnett, MD, FRCP (1)  ·  Selina Luger (1)

Results publications

PMID 19470696

NIH funding

U10CA021115 (1), U10CA180820 (1)